secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2026-07-16T21:30:15+00:00
Accession:  0001493152-26-033593
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements
--------------------------------------------------------------------------------

- CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
- Board appointed director Katharyn Field as CEO, President, and interim CFO; she also serves as CEO of iSpecimen (ISPC).
- Board elected Esha Randhawa and Steven Brown as new directors; committees reconstituted with new chairs.
- Board authorized investigation into negotiation and approval of employment agreements; no severance payments pending outcome.
- Employment agreements amended July 8, 2026 to limit change-in-control severance to only certain transaction types.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000149315226033593/0001493152-26-033593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000149315226033593/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer